AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3148139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3148139 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent articulation
Number of subjects: 20
Study 31862185 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant androgen deprivation therapy (ADT)
Number of subjects: 8
Study 29976358 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1905
Study 29976358 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1905
Study 27652718 — intervention group
Group type: EXPERIMENTAL
Intervention: LTHome
Number of subjects: 139
Study 27652718 — intervention group
Group type: COMPARATOR
Intervention: EUT
Number of subjects: 139
Study 25500337 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg algal DHA supplementation (3 capsules per day)
Number of subjects: 205
Study 25500337 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mixed soy and corn oil)
Number of subjects: 205
Study 25500337 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg algal DHA supplementation
Number of subjects: 205
Study 23069814 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechlorethamine, 0.02%, gel
Number of subjects: 260
Study 23069814 — intervention group
Group type: COMPARATOR
Intervention: Mechlorethamine, 0.02%, compounded ointment
Number of subjects: 260
Study 21911194 — intervention group
Group type: EXPERIMENTAL
Intervention: EasyTube (EzT)
Number of subjects: 80
Study 21911194 — intervention group
Group type: COMPARATOR
Intervention: esophageal-tracheal Combitube (ETC)
Number of subjects: 80
Study 18218285 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-dissolving ibuprofen caplets
Number of subjects: 26
Study 18218285 — intervention group
Group type: COMPARATOR
Intervention: Regular release ibuprofen caplets
Number of subjects: 26
Study 11974477 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention (not specified dosage or duration)
Number of subjects: 3756
Study 9524895 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltanolone
Number of subjects: 75
Study 9524895 — intervention group
Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 75
Study 9524895 — intervention group
Group type: COMPARATOR
Intervention: Etomidate
Number of subjects: 75
Study 8077573 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mmol/L L‐glutamine added to standard WHO oral rehydration salts (WHO‐ORS)
Number of subjects: 120
Study 8077573 — intervention group
Group type: COMPARATOR
Intervention: Standard WHO oral rehydration salts (WHO‐ORS)
Number of subjects: 120
Study 2572120 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid cream (clobetasol propionate)
Number of subjects: 11
Study 2572120 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream (base of the steroid cream)
Number of subjects: 11
Study 796950 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen (administered rectally at a dosage of 200 mg daily)
Number of subjects: 0
Study 796950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28667222 — intervention group
Group type: EXPERIMENTAL
Intervention: PROPEL intervention (group exercise plus self-management)
Number of subjects: 192
Study 28667222 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (group aerobic exercise only)
Number of subjects: 192
Study 26650153 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial valve treatment (EBV group)
Number of subjects: 68
Study 26650153 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard medical care)
Number of subjects: 68
Study 23908086 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (15 mg/d)
Number of subjects: 121
Study 23908086 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vitamin C)
Number of subjects: 121
Study 21890003 — intervention group
Group type: EXPERIMENTAL
Intervention: Added external dead space (DS) 200 mL
Number of subjects: 16
Study 21890003 — intervention group
Group type: EXPERIMENTAL
Intervention: Added external dead space (DS) 400 mL
Number of subjects: 16
Study 21890003 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (no added DS)
Number of subjects: 16
Study 19515882 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting with coronary endarterectomy (Group 1)
Number of subjects: 100
Study 19515882 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting without coronary endarterectomy (Group 2)
Number of subjects: 100
Study 16423677 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral leaflet separation index
Number of subjects: 88
Study 16423677 — intervention group
Group type: COMPARATOR
Intervention: Mitral valve area by planimetry
Number of subjects: 88
Study 16423677 — intervention group
Group type: COMPARATOR
Intervention: Pressure half‐time
Number of subjects: 88
Study 15013037 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg tablet daily for 5 days)
Number of subjects: 162
Study 15013037 — intervention group
Group type: COMPARATOR
Intervention: Co-amoxiclav (625 mg tablet every 8 hours for 7 days)
Number of subjects: 162
Study 15013037 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 162
Study 15013037 — intervention group
Group type: COMPARATOR
Intervention: Co-amoxiclav
Number of subjects: 162
Study 15013037 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin and Co-amoxiclav
Number of subjects: 162
Study 11697377 — intervention group
Group type: EXPERIMENTAL
Intervention: General request for data
Number of subjects: 29
Study 11697377 — intervention group
Group type: COMPARATOR
Intervention: Specific request for data
Number of subjects: 29
Study 9237640 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (60 mg/day)
Number of subjects: 27
Study 8217032 — intervention group
Group type: EXPERIMENTAL
Intervention: lovastatin 20 mg every day
Number of subjects: 293
Study 8217032 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 293
Study 8217032 — intervention group
Group type: COMPARATOR
Intervention: lisinopril
Number of subjects: 293
Study 8217032 — intervention group
Group type: COMPARATOR
Intervention: nifedipine
Number of subjects: 293
Study 8217032 — intervention group
Group type: EXPERIMENTAL
Intervention: lovastatin
Number of subjects: 293
Study 31965873 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (home pharmacist visit, illustrated medication instructions, follow-up phone call)
Number of subjects: 162
Study 31965873 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 162
Study 31965873 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 162
Study 29384470 — intervention group
Group type: EXPERIMENTAL
Intervention: EVAR
Number of subjects: 626
Study 29384470 — intervention group
Group type: COMPARATOR
Intervention: OR
Number of subjects: 626
Study 29384470 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 626
Study 27118453 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation 8-color multiparameter-flow cytometry (MFC) for MRD monitoring
Number of subjects: 162
Study 27118453 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD negativity
Number of subjects: 162
Study 27118453 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune profiling with MRD monitoring
Number of subjects: 162
Study 25434315 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine (LAM)
Number of subjects: 164
Study 25434315 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Number of subjects: 164
Study 25434315 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine (LDT)
Number of subjects: 164
Study 25434315 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine and Adefovir dipivoxil (CLA) combination
Number of subjects: 164
Study 25434315 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with HBV DNA levels below quantitation limit (QL)
Number of subjects: 164
Study 25434315 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with HBV DNA levels detectable but <10(4) copies/mL
Number of subjects: 164
Study 25434315 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with HBV DNA levels >10(4) copies/mL
Number of subjects: 164
Study 22474997 — intervention group
Group type: EXPERIMENTAL
Intervention: Yougui Capsules at 1.68 g tid for 12 weeks
Number of subjects: 80
Study 22474997 — intervention group
Group type: COMPARATOR
Intervention: Wuziyanzong Pills at 6 g bid for 12 weeks
Number of subjects: 80
Study 20823406 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib plus dexamethasone
Number of subjects: 482
Study 20823406 — intervention group
Group type: COMPARATOR
Intervention: VAD
Number of subjects: 482
Study 18619828 — intervention group
Group type: EXPERIMENTAL
Intervention: O(2)
Number of subjects: 25
Study 18619828 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 25
Study 16879073 — intervention group
Group type: EXPERIMENTAL
Intervention: ABL 735 blood gas analyzer
Number of subjects: 0
Study 16879073 — intervention group
Group type: EXPERIMENTAL
Intervention: Omni S blood gas analyzer
Number of subjects: 0
Study 16879073 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapidpoint 405 blood gas analyzer
Number of subjects: 0
Study 16879073 — intervention group
Group type: COMPARATOR
Intervention: ABL 620 blood gas analyzer (control)
Number of subjects: 0
Study 16879073 — intervention group
Group type: COMPARATOR
Intervention: Comparative analysis of new instruments against ABL 620
Number of subjects: 0
Study 12830373 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroperitoneal approach
Number of subjects: 23
Study 12830373 — intervention group
Group type: COMPARATOR
Intervention: Transperitoneal approach
Number of subjects: 23
Study 10606840 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.15 mg kg‐1)
Number of subjects: 6
Study 10606840 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-hydroxy-midazolam (0.15 mg kg‐1)
Number of subjects: 6
Study 10606840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 9148226 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide (20 mg/die)
Number of subjects: 20
Study 9148226 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (50 mg/die)
Number of subjects: 20
Study 9148226 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide (T)
Number of subjects: 20
Study 9148226 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (F)
Number of subjects: 20
Study 8211583 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucan (beta 1-3 polyglucose)
Number of subjects: 41
Study 8211583 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study 2946224 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 300 mg bid
Number of subjects: 23
Study 2946224 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 500 mg bid
Number of subjects: 23
Study 2946224 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam 20 mg qd
Number of subjects: 23
Study 30637887 — intervention group
Group type: EXPERIMENTAL
Intervention: Full intervention (counseling session plus tailored brochure)
Number of subjects: 347
Study 30637887 — intervention group
Group type: COMPARATOR
Intervention: Generic information sheet
Number of subjects: 347
Study 30637887 — intervention group
Group type: COMPARATOR
Intervention: Tailored brochure mailed after the ED visit
Number of subjects: 347
Study 30637887 — intervention group
Group type: COMPARATOR
Intervention: Single motivational interviewing-based counseling session in the ED
Number of subjects: 347
Study 30304118 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive psychotherapy for depression
Number of subjects: 61
Study 27115286 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted quality intervention (education, pathways, local champions, audit-feedback)
Number of subjects: 905
Study 24823902 — intervention group
Group type: EXPERIMENTAL
Intervention: Standalone balloon dilation
Number of subjects: 92
Study 24823902 — intervention group
Group type: COMPARATOR
Intervention: Functional endoscopic sinus surgery (FESS)
Number of subjects: 92
Study 22703741 — intervention group
Group type: EXPERIMENTAL
Intervention: Core Conditioning exercises with the Stretch Pole (SP group)
Number of subjects: 14
Study 22703741 — intervention group
Group type: COMPARATOR
Intervention: Core Conditioning exercises without the Stretch Pole (C group)
Number of subjects: 14
Study 20038911 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone
Number of subjects: 2
Study 20038911 — intervention group
Group type: EXPERIMENTAL
Intervention: Demineralized bone matrix
Number of subjects: 2
Study 20038911 — intervention group
Group type: COMPARATOR
Intervention: Platelet-rich plasma
Number of subjects: 2
Study 20038911 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxyapatite
Number of subjects: 2
Study 20038911 — intervention group
Group type: COMPARATOR
Intervention: Control (no graft)
Number of subjects: 2
Study 18029292 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (SSRI)
Number of subjects: 700
Study 18029292 — intervention group
Group type: COMPARATOR
Intervention: Optimised pharmacotherapy for CHF
Number of subjects: 700
Study 16122909 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment (IT)
Number of subjects: 547
Study 16122909 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (ST)
Number of subjects: 547
Study 12009084 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte depletion by filtration with full-dose aprotinin
Number of subjects: 122
Study 12009084 — intervention group
Group type: COMPARATOR
Intervention: Standard moderate hypothermic blood cardioplegia cardiopulmonary bypass
Number of subjects: 122
Study 10412845 — intervention group
Group type: COMPARATOR
Intervention: Demineralized freeze dried bone allograft (DFDBA)
Number of subjects: 17
Study 10412845 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine derived xenograft (BDX) Bio-Oss
Number of subjects: 17
Study 8520877 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron + Dexamethasone
Number of subjects: 292
Study 8520877 — intervention group
Group type: COMPARATOR
Intervention: Granisetron
Number of subjects: 292
Study 2405343 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline
Number of subjects: 25
Study 2405343 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 25
Study 7246035 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitalis
Number of subjects: 20
Study 29981250 — intervention group
Group type: EXPERIMENTAL
Intervention: Active expiratory muscle strength training (EMST)
Number of subjects: 48
Study 29981250 — intervention group
Group type: COMPARATOR
Intervention: Sham expiratory muscle strength training (EMST)
Number of subjects: 48
Study 28495642 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide therapy (initiated at 5 mg every other day, increased to 10 mg daily if tolerated)
Number of subjects: 17
Study 28495642 — intervention group
Group type: COMPARATOR
Intervention: Standard care (withdrawal of immunosuppression followed by donor lymphocyte infusion)
Number of subjects: 17
Study 25577762 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 0
Study 25577762 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective prediction-based treatment
Number of subjects: 0
Study 23643110 — intervention group
Group type: EXPERIMENTAL
Intervention: Act in Case of Depression (AiD) implemented in somatic units
Number of subjects: 793
Study 23643110 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no intervention) in dementia units
Number of subjects: 793
Study 23643110 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to depression assessment procedures
Number of subjects: 793
Study 23643110 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to treatment pathways
Number of subjects: 793
Study 21257003 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 252
Study 21257003 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg/day
Number of subjects: 252
Study 19415804 — intervention group
Group type: EXPERIMENTAL
Intervention: MAL 160 mg/g with 1 h incubation
Number of subjects: 112
Study 19415804 — intervention group
Group type: EXPERIMENTAL
Intervention: MAL 160 mg/g with 3 h incubation
Number of subjects: 112
Study 19415804 — intervention group
Group type: COMPARATOR
Intervention: MAL 80 mg/g
Number of subjects: 112
Study 17895456 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephonic outreach and care management program
Number of subjects: 604
Study 17895456 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 604
Study 12583920 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatization Disorder (SD)
Number of subjects: 0
Study 12583920 — intervention group
Group type: EXPERIMENTAL
Intervention: Abridged Somatization Disorder (ASD)
Number of subjects: 0
Study 12583920 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisomatoform Disorder (MSD)
Number of subjects: 0
Study 12583920 — intervention group
Group type: EXPERIMENTAL
Intervention: All three groups (SD, ASD, MSD)
Number of subjects: 0
Study 12583920 — intervention group
Group type: COMPARATOR
Intervention: General population
Number of subjects: 0
Study 10708198 — intervention group
Group type: EXPERIMENTAL
Intervention: CCM elective intervention
Number of subjects: 40
Study 9506002 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (50 mg every 8 hours for 7 days)
Number of subjects: 16
Study 9506002 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.5 g/kg on days 5 and 7)
Number of subjects: 16
Study 9506002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8292113 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion
Number of subjects: 475
Study 8292113 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic blood transfusion
Number of subjects: 475
Study 8292113 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusions (both types)
Number of subjects: 475
Study 2428288 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium tetraborate
Number of subjects: 26
Study 2428288 — intervention group
Group type: EXPERIMENTAL
Intervention: Alum
Number of subjects: 26
Study 31659242 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamon supplementation (3g daily)
Number of subjects: 44
Study 31659242 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3g daily)
Number of subjects: 44
Study 27932411 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD-4023 (once-weekly dosing at 18.5%, 37%, 55.5%, or 123.4% of individual cumulative weekly molar hGH dose)
Number of subjects: 54
Study 27932411 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD-4023 (once-weekly dosing at 61.7% molar hGH content during Stage B)
Number of subjects: 54
Study 27932411 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD-4023 (various dosing cohorts)
Number of subjects: 54
Study 25754018 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel X-ray imaging technology
Number of subjects: 70
Study 25754018 — intervention group
Group type: COMPARATOR
Intervention: Reference X-ray system
Number of subjects: 70
Study 23441963 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg extract Sceletium tortuosum (Zembrin)
Number of subjects: 37
Study 23441963 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg extract Sceletium tortuosum (Zembrin)
Number of subjects: 37
Study 23441963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 21046132 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CA-125 concentrations in preeclamptic pregnancies (mild and severe)
Number of subjects: 242
Study 19416039 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (100 mg/d during weeks 1-2, 200 mg during weeks 3-4)
Number of subjects: 0
Study 19416039 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 0
Study 17081839 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-content labels on non-energy-containing beverage selection panels
Number of subjects: 8
Study 17081839 — intervention group
Group type: EXPERIMENTAL
Intervention: Labels plus motivational posters
Number of subjects: 8
Study 17081839 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 8
Study 14691579 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting plus abciximab
Number of subjects: 292
Study 14691579 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis (alteplase alone or alteplase plus abciximab)
Number of subjects: 292
Study 14691579 — intervention group
Group type: COMPARATOR
Intervention: Pl(A2) allele carriers
Number of subjects: 292
Study 14691579 — intervention group
Group type: COMPARATOR
Intervention: Pl(A1/A1) patients
Number of subjects: 292
Study 9621781 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized diet with adjusted energy intake, increased fish and antioxidants
Number of subjects: 109
Study 9621781 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specialized diet)
Number of subjects: 109
Study 7800355 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment groups (specific treatments not detailed in the abstract)
Number of subjects: 438
Study 3279747 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose (120 g)
Number of subjects: 10
Study 3279747 — intervention group
Group type: EXPERIMENTAL
Intervention: Starch (120 g)
Number of subjects: 10
Study 3279747 — intervention group
Group type: COMPARATOR
Intervention: Fat + Protein meal
Number of subjects: 10
Study 31821992 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised progressive stabilization exercise (SE)
Number of subjects: 40
Study 31821992 — intervention group
Group type: COMPARATOR
Intervention: General exercise (GE)
Number of subjects: 40
Study 29170904 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise training (ET group) for 5 weeks
Number of subjects: 20
Study 29170904 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control (SC group)
Number of subjects: 20
Study 29170904 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise training (ET group)
Number of subjects: 20
Study 28341069 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgery
Number of subjects: 165
Study 28341069 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided corticosteroid injection
Number of subjects: 165